Anal Cancer
Anal cancer typically arises from the squamous cells lining the anal canal, often associated with persistent HPV infection.
It’s a relatively uncommon but highly treatable cancer when diagnosed early.
Modern therapy emphasizes combined chemoradiation over surgery, preserving function and achieving excellent local control rates.
Overview And Clinical Background
Epidemiology and pathology
Anal cancer is mostly squamous cell carcinoma, distinct from rectal adenocarcinoma.
HPV 16 is the primary causative agent, along with risk factors such as smoking, immunosuppression, and chronic irritation.
Symptoms, Signs And Presentation
Anal cancer may be mistaken for benign conditions like hemorrhoids early on.
Awareness of persistent symptoms leads to earlier diagnosis.
Diagnosis Methods And Investigations
Imaging and pathology confirmation
Definitive diagnosis is made by biopsy, followed by staging with imaging to plan therapy.
Pelvic MRI and PET-CT help define local extent and metastasis.
Treatment Options And Surgical Techniques
Most patients are treated with combined chemoradiation to preserve the anal sphincter.
Surgery is reserved for residual or recurrent disease.
Recovery, Risks And Prognosis
Prognosis is excellent for early-stage disease, with high cure rates.
Chronic bowel irritation and local discomfort are potential long-term effects of radiation.
Why Choose Us
CureU Healthcare’s multidisciplinary oncology team uses organ-preserving therapy and precision radiotherapy to maximize cure rates while maintaining function.
Supportive care minimizes side effects and improves quality of life.
Conclusion
Anal cancer is highly treatable with early diagnosis and proper multimodal care.
Integrated chemoradiation offers both cure and sphincter preservation.
